Clinical-scale generation of dendritic cells in a closed system

Journal of Immunotherapy

Volumn 26, Issue 4, 2003, Pages 374-383

  Sorg, Rüdiger V ^a   Özcan, Zakir ^a   Fischer, Johannes ^a   Ackermann, Rolf ^a   Müller, Mirko ^a   Wernet, Peter ^a  

^a Heinrich Heine University Medical Center   (France)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; CD11 ANTIGEN; CD18 ANTIGEN; CD40 ANTIGEN; CD86 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CCR7; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HLA ANTIGEN CLASS 1; HLA DR ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 6; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 3; PROSTAGLANDIN E2; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN EXPRESSION; ARTICLE; CASE REPORT; CELL PROLIFERATION; CELL STRUCTURE; CELL VIABILITY; DENDRITIC CELL; HUMAN; HUMAN CELL; IMMUNOMAGNETIC SEPARATION; KIDNEY CARCINOMA; LEUKAPHERESIS; LEUKOCYTE; MALE; MONOCYTE; PHENOTYPE; PRIORITY JOURNAL; PROSTATE CARCINOMA; T LYMPHOCYTE;

ANTIBODIES, MONOCLONAL; ANTIGENS; ANTIGENS, CD; ANTIGENS, CD14; BLOOD COMPONENT REMOVAL; CELL CULTURE TECHNIQUES; CELL DIFFERENTIATION; CELL SEPARATION; CHEMOKINES; CYCLIC GMP; DENDRITIC CELLS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; IMMUNOTHERAPY; LEUKAPHERESIS; LEUKOCYTES; MALE; MONOCYTES; NEOPLASM METASTASIS; PHENOTYPE; T-LYMPHOCYTES; TIME FACTORS; UP-REGULATION;

EID: 0037491839     PISSN: 15249557     EISSN: 15374513     Source Type: Journal    
DOI: 10.1097/00002371-200307000-00010     Document Type: Article

References (47)

1. Banchereau J, Briere F, Caux C, et al. Immunobiology of dendritic cells. Annu Rev Immunol. 2000; 18:767-811.
2. Matzinger P. Tolerance, danger, and the extended family. Annu Rev Immunol. 1994; 12:991-1045.
3. Steinman RM, Dhodapkar M. Active immunization against cancer with dendritic cells: the near future. Int J Cancer. 2001; 94:459-473.
4. Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med. 1996; 2:52-58.
5. Nestle FO, Alijagic S, Gilliet M, et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nat Med. 1998; 4:328-332.
6. Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J Exp Med. 1999; 190:1669-1678.
7. Holtl L, Rieser C, Papesh C, et al. Cellular and humoral immune responses in patients with metastatic renal cell carcinoma after vaccination with antigen pulsed dendritic cells. J Urol. 1999; 161:777-782.
8. Tjoa BA, Simmons SJ, Elgamal A, et al. Follow-up evaluation of a phase II prostate cancer vaccine trial. Prostate. 1999; 40:125-129.
9. Mutis T, Verdijk R, Schrama E, et al. Feasibility of immunotherapy of relapsed leukemia with ex vivo-generated cytotoxic T lymphocytes specific for hematopoietic system-restricted minor histocompatibility antigens. Blood. 1999; 93:2336-2341.
10. Oelke M, Moehrle U, Chen JL, et al. Generation and purification of CD8+ melan-A-specific cytotoxic T lymphocytes for adoptive transfer in tumor immunotherapy. Clin Cancer Res. 2000; 6:1997-2005.
11. Kurokawa T, Oelke M, Mackensen A. Induction and clonal expansion of tumor-specific cytotoxic T lymphocytes from renal cell carcinoma patients after stimulation with autologous dendritic cells loaded with tumor cells. Int J Cancer. 2001; 91:749-756.
12. Thomas R, Davis LS, Lipsky PE. Isolation and characterization of human peripheral blood dendritic cells. J Immunol. 1993; 150:821-834.
13. Siena S, Di Nicola M, Bregni M, et al. Massive ex vivo generation of functional dendritic cells from mobilized CD34+ blood progenitors for anticancer therapy. Exp Hematol. 1995; 23:1463-1471.
14. Romani N, Gruner S, Brang D, et al. Proliferating dendritic cell progenitors in human blood. J Exp Med. 1994; 180:83-93.
15. Sallusto F, Lanzavecchia A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor alpha. J Exp Med. 1994; 179:1109-1118.
16. Romani N, Reider D, Heuer M, et al. Generation of mature dendritic cells from human blood. An improved method with special regard to clinical applicability. J Immunol Methods. 1996; 196:137-151.
17. Bender A, Sapp M, Schuler G, et al. Improved methods for the generation of dendritic cells from nonproliferating progenitors in human blood. J Immunol Methods. 1996; 196:121-135.
18. Thurner B, Roder C, Dieckmann D, et al. Generation of large numbers of fully mature and stable dendritic cells from leukapheresis products for clinical application. J Immunol Methods. 1999; 223:1-15.
19. Bernard J, Ittelet D, Christoph A, et al. Adherent-free generation of functional dendritic cells from purified blood monocytes in view of potential clinical use. Hematol Cell Ther. 1998; 40:17-26.
20. Padley DJ, Dietz AB, Gastineau DA, et al. Mature myeloid dendritic cells for clinical use prepared from CD14+ cells isolated by immunomagnetic adsorption. J Hematother Stem Cell Res. 2001; 10:427-429.
21. Suen Y, Lee SM, Aono F, et al. Comparison of monocyte enrichment by immuno-magnetic depletion or adherence for the clinical-scale generation of DC. Cytotherapy. 2001; 3:365-375.
22. Sloand EM, Kim S, Maciejewski JP, et al. Pharmacologic doses of granulocyte colony-stimulating factor affect cytokine production by lymphocytes in vitro and in vivo. Blood. 2000; 95:2269-2274.
23. Nishimura T, Iwakabe K, Sekimoto M, et al. Distinct role of antigen-specific T helper type 1 (Th1) and Th2 cells in tumor eradication in vivo. J Exp Med. 1999; 190:617-627.
24. Jonuleit H, Kuhn U, Muller G, et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur J Immunol. 1997; 27:3135-3142.
25. Pickl WF, Majdic O, Kohl P, et al. Molecular and functional characteristics of dendritic cells generated from highly purified CD14+ peripheral blood monocytes. J Immunol. 1996; 157:3850-3859.
26. Dhodapkar MV, Krasovsky J, Steinman RM, et al. Mature dendritic cells boost functionally superior CD8(+) T-cell in humans without foreign helper epitopes. J Clin Invest. 2000; 105:R9-R14.
27. Caux C, Ait-Yahia S, Chemin K, et al. Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. Springer Semin Immunopathol. 2000; 22:345-369.
28. Steinbrink K, Wolfl M, Jonuleit H, et al. Induction of tolerance by IL-10-treated dendritic cells. J Immunol. 1997; 159:4772-4780.
29. Jonuleit H, Schmitt E, Schuler G, et al. Induction of interleukin 10-producing, nonproliferating CD4(+) T cells with regulatory properties by repetitive stimulation with allogeneic immature human dendritic cells. J Exp Med. 2000; 192:1213-1222.
30. Dhodapkar MV, Steinman RM, Krasovsky J, et al. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J Exp Med. 2001; 193:233-238.
31. Sorg RV, Andres S, Kögler G, et al. Phenotypic and functional comparison of monocytes from cord blood and granulocyte colony-stimulating factor-mobilized apheresis products. Exp Hematol. 2001; 29:1289-1294.
32. McLellan AD, Heiser A, Hart DN. Induction of dendritic cell costimulator molecule expression is suppressed by T cells in the absence of antigen-specific signalling: role of cluster formation, CD40 and HLA-class II for dendritic cell activation. Immunology. 1999; 98:171-180.
33. Reik RA, Noto TA, Fernandez HF. Safety of large-volume leukapheresis for collection of peripheral blood progenitor cells. J Clin Apheresis. 1997; 12:10-13.
34. Nagase K, Sawada K, Ohnishi K, et al. Complications of leukocytapheresis. Ther Apher. 1998; 2:120-124.
35. Nestle FO, Banchereau J, Hart D. Dendritic cells: On the move from bench to bedside. Nat Med. 2001; 7:761-765.
36. Cao H, Verge V, Baron C, et al. In vitro generation of dendritic cells from human blood monocytes in experimental conditions compatible for in vivo cell therapy. J Hematother Stem Cell Res. 2000; 9:183-194.
37. Tuyaerts S, Noppe SM, Corthals J, et al. Generation of large numbers of dendritic cells in a closed system using Cell Factories. J Immunol Methods. 2002; 264:135-151.
38. Berger T, Feuerstein B, Strasser E, et al. Large-scale generation of mature monocyte-derived dendritic cells for clinical application in cell factories. J Immunol Methods. 2002; 268:131-140.
39. Nguyen XD, Eichler H, Sucker A, et al. Collection of autologous monocytes for dendritic cell vaccination therapy in metastatic melanoma patients. Transfusion (Paris). 2002; 42:428-432.
40. Toungouz M, Quinet C, Thille E, et al. Generation of immature autologous clinical grade dendritic cells for vaccination of cancer patients. Cytotherapy. 1999; 1:447-453.
41. Chomarat P, Banchereau J, Davoust J, et al. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nat Immunol. 2000; 1:510-514.
42. Andreesen R, Picht J, Lohr GW. Primary cultures of human blood-born macrophages grown on hydrophobic teflon membranes. J Immunol Methods. 1983; 56:295-304.
43. Loudovaris M, Hansen M, Suen Y, et al. Differential effects of autologous serum on CD34(+) or monocyte-derived dendritic cells. J Hematother Stem Cell Res. 2001; 10:569-578.
44. Zhou LJ, Tedder TF. Human blood dendritic cells selectively express CD83, a member of the immunoglobulin superfamily. J Immunol. 1995; 154:3821-3835.
45. Zhou LJ, Tedder TF. CD14+ blood monocytes can differentiate into functionally mature CD83+ dendritic cells. Proc Natl Acad Sci USA. 1996; 93:2588-2592.
46. de Saint-Vis B, Vincent J, Vandenabeele S, et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC maturation, is transiently expressed in MHC class II compartment. Immunity. 1998; 9:325-336.
47. Lipscomb MF, Masten BJ. Dendritic cells: immune regulators in health and disease. Physiol Rev. 2002; 82:97-130.